Laigo Bio secures Health~Holland PPP Innovation Subsidy for Advancing Targeted Protein Degradation

Translating SureTACs to the clinic

Laigo Bio has been awarded a TKI-MKB (SME) grant to further develop its SureTAC technology in collaboration with UMC Utrecht and Oncode Institute. This funding will support critical steps in optimizing SureTAC molecules, pushing them through the lead optimization phase and bringing them to the development candidate nomination stage. This will pave the way for further clinical development by Laigo Bio to promptly move promising compounds into the clinic.

The Dutch Top Sector Life Sciences & Health (LSH) encourages innovative research by (financially) supporting public-private partnerships (PPP) in the life sciences & health sector and the Top Consortium Knowledge and Innovation (TKI) office is the operating body that awards TKI-MKB (SME) subsidies to support collaborative R&D projects of enterprises and research organizations.

For more information: https://www.health-holland.com/project/2024/2024/translating-suretacs-clinic-improved-cancer-treatment